Greenland Mines (NASDAQ: GRML) announced today that IP Australia has granted Australian Patent No. 2023252508, covering gene therapy technology exclusively licensed by the company's Biotech Division for the treatment of neuromuscular diseases through expression of the human Klotho protein. The patent strengthens the intellectual property supporting Greenland Mines' Klotho-based therapeutic platform and includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems.
The company said the patent further supports development of its KLTO-202 program targeting amyotrophic lateral sclerosis (ALS) and other neuromuscular disorders. The granted patent provides protection in a key jurisdiction, potentially expanding the company's ability to commercialize its gene therapy platform internationally. The technology utilizes the Klotho protein, which has been studied for its potential anti-aging and neuroprotective effects, and Greenland Mines is leveraging it to address serious neuromuscular conditions with high unmet medical need.
The announcement comes as Greenland Mines continues to advance its dual business strategy, with a mining division focused on rare earth and precious metal projects in Greenland and a biotech division centered on the Klotho platform. The company's Skaergaard Project in southeast Greenland and the pending acquisition of the Sarfartoq neodymium-praseodymium project highlight its mining ambitions, while the biotech division aims to capitalize on the growing gene therapy market. According to the company, the patent grant is a significant milestone for the KLTO-202 program and validates the innovative approach to treating ALS, a progressive neurodegenerative disease with limited treatment options.
Greenland Mines' strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure. The biotech division's progress with the Klotho platform adds a potentially high-value asset that diversifies the company's risk profile and could generate significant returns if clinical trials prove successful.
The company cautioned that forward-looking statements in the announcement involve risks and uncertainties, including factors that may cause actual results to differ materially from expectations. These include risks related to the development and commercialization of gene therapy products, regulatory approvals, and the company's ability to secure additional financing. For more details, the full press release is available at https://nnw.fm/PVbbH and the company's newsroom at https://ibn.fm/GRML.
